Author
Listed:
- Xiaojie Xu
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine
Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University)
- Zhongyi Fan
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine
PLA General Hospital)
- Chaoyang Liang
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine
Hainan Branch of PLA General Hospital)
- Ling Li
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine)
- Lili Wang
(Medical Research Center of Shengjing Hospital, China Medical University)
- Yingchun Liang
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine)
- Jun Wu
(Beijing Institute of Biotechnology)
- Shaohong Chang
(Beijing Institute of Biotechnology)
- Zhifeng Yan
(PLA General Hospital)
- Zhaohui Lv
(PLA General Hospital)
- Jing Fu
(PLA General Hospital)
- Yang Liu
(PLA General Hospital)
- Shuai Jin
(PLA General Hospital)
- Tao Wang
(307 Hospital of People’s Liberation Army)
- Tian Hong
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine)
- Yishan Dong
(Peking University Cancer Hospital & Institute)
- Lihua Ding
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine)
- Long Cheng
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine)
- Rui Liu
(The First Affiliated Hospital of Xi’an Jiao Tong University)
- Shenbo Fu
(The First Affiliated Hospital of Xi’an Jiao Tong University)
- Shunchang Jiao
(PLA General Hospital)
- Qinong Ye
(Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine
Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University)
Abstract
Tumour radiotherapy resistance involves the cell cycle pathway. CDC25 phosphatases are key cell cycle regulators. However, how CDC25 activity is precisely controlled remains largely unknown. Here, we show that LIM domain-containing proteins, such as FHL1, increase inhibitory CDC25 phosphorylation by forming a complex with CHK2 and CDC25, and sequester CDC25 in the cytoplasm by forming another complex with 14-3-3 and CDC25, resulting in increased radioresistance in cancer cells. FHL1 expression, induced by ionizing irradiation in a SP1- and MLL1-dependent manner, positively correlates with radioresistance in cancer patients. We identify a cell-penetrating 11 amino-acid motif within LIM domains (eLIM) that is sufficient for binding CHK2 and CDC25, reducing the CHK2–CDC25 and CDC25–14-3-3 interaction and enhancing CDC25 activity and cancer radiosensitivity accompanied by mitotic catastrophe and apoptosis. Our results provide novel insight into molecular mechanisms underlying CDC25 activity regulation. LIM protein inhibition or use of eLIM may be new strategies for improving tumour radiosensitivity.
Suggested Citation
Xiaojie Xu & Zhongyi Fan & Chaoyang Liang & Ling Li & Lili Wang & Yingchun Liang & Jun Wu & Shaohong Chang & Zhifeng Yan & Zhaohui Lv & Jing Fu & Yang Liu & Shuai Jin & Tao Wang & Tian Hong & Yishan D, 2017.
"A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity,"
Nature Communications, Nature, vol. 8(1), pages 1-14, April.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14059
DOI: 10.1038/ncomms14059
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14059. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.